November 2020
TACTI-Mel (Efti and Keytruda) phase 1 - 24 patients with advanced melanoma.
Safety and dose escalation - primary endpoints
But note efficacy - 66% of patients progression free after 6 months. (follow-up 12 month PFS data due circa May 2021).
BMS - Opdivo and Relatlimab (PD-1 and anti Lag-3) combo in melanoma P3 - 700 patients met PFS goal (not yet disclosed).
Of interest - Opdivo in combo with Yervoy (PD-1 and CTLA checkpoint inhibitors) - 33% patients progression free after 12 months.
90 cents is the price target, page-14
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $443.6M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 31.8¢ | 30.3¢ | $1.189M | 3.864M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78803 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 1155 | 1 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |